Alzheimer's disease
Pioneering tau-focused therapies to redefine Alzheimer’s treatment
Reducing the levels of aggregated tau proteins
Our second-generation tau aggregation inhibitor (TAI) has been submitted for approval to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. NHS treatments for Alzheimer’s only temporarily address the symptoms and do not slow disease progression. Our investigational drug, hydromethylthionine mesylate (HMTM), acts by reducing levels of aggregated or misfolded tau proteins, which are associated with the progressive neurodegeneration that is the hallmark of Alzheimer’s disease.
3,000 participants studied
HMTM shares the same active ingredient and mode of action as our first generation TAI. Phase II clinical trials provided the first clinical demonstration that a new therapy targeting protein aggregation could reduce the rate of progression of this deadly disease. We have completed a global Phase III clinical trial, LUCIDITY, and presented the results at the 2024 Alzheimer’s and Parkinson’s Diseases Conference in Lisbon, Portugal. The evidence gathered from trials and other programmes involving over 3,000 participants indicates HMTM has a strong safety profile and could be delivered with minimal patient and physician burden.
